Kardigan, Inc.

$KARD·$1.9B·Biotechnology·Healthcare

$22.00+37.5%1Y0.0%

Mentions · last 7 days

Price updated 12m ago

Loading…

What it does

Plain-English summary of the business — what they sell and how they make money.

Kardigan is a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen.

Industry overviewAI analysis

Where Biotechnology sits in its cycle right now — and what that implies for $KARD.

Biotechnology · Healthcare

GLP-1 obesity pipeline competition is the dominant structural driver — the 'next phase' of obesity drugs (oral formulations, differentiated mechanisms) is reshaping clinical bets for NVO competitors. Gene editing (CRSP, BEAM, NTLA, PRME) is transitioning from clinical to commercial-maturation phase with Casgevy scaling; oncology binary events (IBRX, ALLO, KURA) define the near-term calendar.

Top industry ETF

$IBBiShares Biotechnology ETF

+2.4%YTD

+38.1%1Y

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

424B4Prospectus supplement (offering)Jun 18

AI summary

Kardigan Inc. (KARD) priced its IPO at $16.00 per share, selling 25,000,000 shares for gross proceeds of $400 million ($372 million net after underwriting discounts). An overallotment option covers an additional 3,750,000 shares. Shares are listed on Nasdaq under 'KARD'; delivery was expected around June 22, 2026. Joint book-running managers are JP Morgan, Jefferies, Leerink Partners, and TD Cowen. Kardigan is a pharmaceutical company (SIC 2834) incorporated in Delaware and headquartered in Princeton, NJ.

3New insider — initial holdingsJun 18

AI summary

Perceptive Advisors LLC filed an initial Form 3 as a 10%-plus beneficial owner of Kardigan Inc. (KARD) in connection with the company's IPO on June 18, 2026. This is a routine large-holder ownership disclosure with no open-market transactions reported.

3New insider — initial holdingsJun 18

AI summary

Brianne Jahn filed an initial Form 3 as an insider of Kardigan Inc. (KARD) in connection with the company's IPO on June 17, 2026. This is a routine insider ownership disclosure with no open-market transactions reported.

3New insider — initial holdingsJun 18

AI summary

Paul L. Berns filed an initial Form 3 as an insider of Kardigan Inc. (KARD) in connection with the company's IPO on June 17, 2026. This is a routine insider ownership disclosure with no open-market transactions reported.

3New insider — initial holdingsJun 18

AI summary

Andy Pasternak filed an initial Form 3 as an insider of Kardigan Inc. (KARD) in connection with the company's IPO on June 17, 2026. This is a routine insider ownership disclosure with no open-market transactions reported.

3New insider — initial holdingsJun 18

AI summary

Timothy Walbert filed an initial Form 3 as an insider of Kardigan Inc. (KARD) in connection with the company's IPO on June 17, 2026. This is a routine insider ownership disclosure with no open-market transactions reported.

3New insider — initial holdingsJun 18

AI summary

David Meeker filed an initial Form 3 as an insider of Kardigan Inc. (KARD) in connection with the company's IPO on June 17, 2026. This is a routine insider ownership disclosure with no open-market transactions reported.

3New insider — initial holdingsJun 18

AI summary

Kimberly Popovits filed an initial Form 3 as an insider of Kardigan Inc. (KARD) in connection with the company's IPO on June 17, 2026. This is a routine insider ownership disclosure with no open-market transactions reported.

+ 15 other (6 3s · 1 S-1MEF · 1 EFFECT · 1 S-8) in window